phase 2_completion
saveVertex Pharmaceuticals Inc — VX-993 (Phase II Trial Completion)
community read0 votes
Therapy area: Central Nervous System. Indication: Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- earningsVertex, Inc. earningsMay 7, 2026
- approvalTRIKAFTA (COPACKAGED): TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalMar 27, 2026
- approval(deutivacaftor + tezacaftor + vanzacaftor calcium): ALYFTREK (DEUTIVACAFTOR) — FDA approvalMar 27, 2026
- approvalTRIKAFTA (COPACKAGED): TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalMar 27, 2026
- approvalKALYDECO (IVACAFTOR) — FDA approvalMar 17, 2026
- approvalivacaftor: SYMDEKO (COPACKAGED) (IVACAFTOR) — FDA approvalMar 17, 2026
comments(0)
5-min edit window · permanent after that